SFM
NRIX icon

Sphera Funds Management’s Nurix Therapeutics NRIX Stock Holding History

Sphera Funds Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-124,000
Closed -$2.35M – 109
2025
Q4 		$2.35M Buy
+124,000
New +$1.78M 0.45% 69
2021
Q3 		– Sell
-244,157
Closed -$6.48M – 140
2021
Q2 		$6.48M Buy
244,157
+29,081
+14% +$854K 0.44% 63
2021
Q1 		$6.69M Buy
+215,076
New +$8.14M 0.51% 61
2020
Q4 		– Sell
-22,480
Closed -$785K – 126
2020
Q3 		$785K Buy
+22,480
New +$567K 0.08% 89

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Sphera Funds Management's NRIX Position: Q1 2026 in Review

Sphera Funds Management sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 124,000 shares — an estimated $2.35M sold.

Sphera Funds Management first reported a position in NRIX in Q3 2020 and held it in 4 quarters. The position peaked at $6.69M in Q1 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Sphera Funds Management reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sphera Funds Management sold 124,000 Nurix Therapeutics shares in Q1 2026, an estimated $2.35M.
  • Sphera Funds Management first reported a position in Nurix Therapeutics in Q3 2020 and held it in 4 quarters.
  • Sphera Funds Management's Nurix Therapeutics position peaked at $6.69M in Q1 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.